Efavirenz News and Research

RSS
Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
New insights into the mechanisms of efavirenz-induced neurotoxicity

New insights into the mechanisms of efavirenz-induced neurotoxicity

Cholesterol loss in inner ear linked to age-related hearing loss

Cholesterol loss in inner ear linked to age-related hearing loss

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

Use of antiviral and antiretroviral medication could have detrimental impact on crops

Use of antiviral and antiretroviral medication could have detrimental impact on crops

HIV 'wonder drug' may not be as effective as hoped in sub-Saharan Africa, study suggests

HIV 'wonder drug' may not be as effective as hoped in sub-Saharan Africa, study suggests

Dolutegravir is a first-line treatment for people newly diagnosed with HIV

Dolutegravir is a first-line treatment for people newly diagnosed with HIV

The role of brain cells in spreading HIV

The role of brain cells in spreading HIV

Newer antiretroviral drugs may be the safest, most effective HIV treatment during pregnancy

Newer antiretroviral drugs may be the safest, most effective HIV treatment during pregnancy

Children born to women on HIV therapy more likely to have microcephaly, developmental delays

Children born to women on HIV therapy more likely to have microcephaly, developmental delays

New research may help treat HIV patients without elevating risk for liver disease

New research may help treat HIV patients without elevating risk for liver disease

Low doses of anti-HIV drug appear to reduce tau protein in neurons of Alzheimer’s patients

Low doses of anti-HIV drug appear to reduce tau protein in neurons of Alzheimer’s patients

NIH launches large study to compare treatments for pregnant women with HIV

NIH launches large study to compare treatments for pregnant women with HIV

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Cholesterol-processing enzyme could be therapeutic target to stave off neurologic diseases

Cholesterol-processing enzyme could be therapeutic target to stave off neurologic diseases

New trial examines use of nanotechnology to improve delivery of drugs to HIV patients

New trial examines use of nanotechnology to improve delivery of drugs to HIV patients

Added benefit of combination drug for HIV-infected patients not proven

Added benefit of combination drug for HIV-infected patients not proven

Tiny doses of anti-HIV drug may be effective for treating Alzheimer's disease

Tiny doses of anti-HIV drug may be effective for treating Alzheimer's disease

Nearly half of newly-infected HIV patients experience neurologic issues

Nearly half of newly-infected HIV patients experience neurologic issues

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Nurse-trainer uses new approach to teach correct combination of HIV drugs to Angola's nurses

Nurse-trainer uses new approach to teach correct combination of HIV drugs to Angola's nurses

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.